NEWS 112 FEED & ADDITIVE MAGAZINE September 2024 Novus representatives recently presented the 2024 Novus Outstanding Teaching Award to Michael D. Cressman, Ph.D., of the Ohio State University during the Poultry Science Association (PSA) Annual Meeting in Kentucky, USA. As one of the leaders in intelligent nutrition, Novus has been a longtime sponsor of the award that recognizes a PSA member who demonstrates outstanding success in the classroom as well as a dedication to professional improvement and industry excellence. “Through this award, we recognize educators who have dedicated their professional lives to advancing animal agriculture inside the classroom and beyond it,” said Gabriela Cardoso, Ph.D., Novus Poultry Solutions Manager for the Americas who presented the award. “The NOVUS Outstanding Teaching Award winner supports the future of our industry in the impact they have on their students.” Dr. Cressman is a Professional Practice Associate Professor in the Department of Animal Sciences at The Ohio State University (OSU), where his appointment has him spend 75% of his time teaching and 25% on OSU Extension responsibilities. He is also responsible for undergraduate student advising, co-curricular team coaching (poultry judging), undergraduate and graduate student research advising in the areas of applied poultry and meat science, and poultry youth program development in collaboration with FFA, 4-H, and Ohio State Extension faculty and staff members. Heavily embedded in student development, Cressman has held his current position since 2015 and has gained valuable insight he puts into practice in the classroom. Read more>> Novus awards animal ag educator during poultry meeting One of the global leaders in animal health, Elanco Animal Health Incorporated announced a 25,000-square-foot expansion of its biologics manufacturing facility in Elwood, Kansas, USA. The expected $130 million investment through 2026 will enable further growth of the company’s monoclonal antibody (mAb) platform, building on the robust expertise already present at this facility, the company explains. “Expanding the capabilities at our Elwood manufacturing site is a critical step toward executing the most exciting pipeline in Elanco’s 70-year history,” says Grace McArdle, Executive Vice President, Manufacturing and Quality for Elanco. “In partnership with our Elanco R&D colleagues, this site plays a key role in delivering solutions that are transforming the way veterinarians and pet owners care for the world’s animals. We appreciate the commitment of the State of Kansas, Doniphan County and the City of Elwood to help pets live longer, healthier, more active lives.” Currently, Elanco’s Elwood facility plays a crucial role in manufacturing and shipping its Canine Parvovirus Monoclonal Antibody (CPMA), according to the company’s statement. Parvovirus is estimated to affect more than 330,000 puppies a year1 with a mortality rate as high as high as 91% if left untreated2. CPMA is the first and only USDA conditionally approved, targeted treatment for canine parvovirus. This is Elanco’s first mAb in the market with plans for future innovation in this technology platform. Read more>> Elanco unveils $130 million investment to expand mAb production capacity
RkJQdWJsaXNoZXIy MTUxNjkxNQ==